FrancophonIA/ELRC3.0 huggingface dataset:
English: This means that Rivastigmine 3M Health Care Ltd is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon.
Croatian: To znači da je Rivastigmine 3M Health Care Ltd sličan „referetnom lijeku” koji je već odobren u Europskoj uniji (EU) naziva Exelon.
English: Rivastigmine 3M Health Care Ltd can only be obtained with a prescription and is available as transdermal patches, which release either 4.6 or 9.5 mg rivastigmine across the skin over 24 hours.
Croatian: Rivastigmine 3M Health Care Ltd izdaje se samo na liječnički recept i dostupan je u obliku transdermalnih flastera, koji otpuštaju 4,6 ili 9,5 mg rivastigmina kroz kožu tijekom 24 sata.
English: Treatment with Rivastigmine 3M Health Care Ltd should be started and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's dementia.
Croatian: Liječenje lijekom Rivastigmine 3M Health Care Ltd treba započeti i nadgledati liječnik s iskustvom u dijagnosticiranju i liječenju Alzheimerove demencije.
English: Rivastigmine 3M Health Care Ltd is used to treat patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Croatian: Rivastigmine 3M Health Care Ltd koristi se za liječenje bolesnika oboljelih od blage do umjereno teške Alzheimerove demencije, progresivnog poremećaja mozga koji postepeno utječe na pamćenje. intelektualnu sposobnost i ponašanje.
English: Treatment should only be started if a caregiver is available who will regularly give and monitor the use of Rivastigmine 3M Health Care Ltd by the patient.
Croatian: Liječenje treba započeti jedino ako postoji njegovatelj koji će redovito davati i pratiti uzimanje lijeka Rivastigmine 3M Health Care Ltd od strane bolesnika.
English: This is a summary of the European public assessment report (EPAR) for Rivastigmine 3M Health Care Ltd.
Croatian: Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Rivastigmine 3M Health Care Ltd.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rivastigmine 3M Health Care Ltd, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana u sažetak opisa svojstava lijeka kao i u uputu o lijeku, za lijek Rivastigmine 3M Health Care Ltd uključene su sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju primjenjivati.
English: Treatment should be started with the 4.6-mg-per-24-hours patch, with the dose increased to the higher strength 9.5 mg/24-h patch after at least four weeks if the lower dose is well tolerated.
Croatian: Nakon najmanje četiri tjedna liječenja te ako se lijek dobro podnosi, dozu od 4,6 mg/24 h potrebno je povećati na 9,5 mg/24 h.
English: Because Rivastigmine 3M Health Care Ltd is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Rivastigmine 3M Health Care Ltd generički lijek, te je bioekvivalent s referentnim lijekom, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: The active substance in Rivastigmine 3M Health Care Ltd, rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
Croatian: Djelatna tvar lijeka Rivastigmine 3M Health Care Ltd, rivastigmin djeluje blokirajući enzime koji razgrađuju acetilkolin: acetilkolinesterazu i butirilkolinesterazu.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine 3M Health Care Ltd on 3 April 2014.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Rivastigmine 3M Health Care Ltd vrijedi na prostoru Europske unije od 03. travnja 2014.
English: For more information about treatment with Rivastigmine 3M Health Care Ltd, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Rivastigmine 3M Health Care Ltd pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Rivastigmine 3M Health Care Ltd is a ‘generic medicine'.
Croatian: Rivastigmine 3M Health Care Ltd je „generički lijek”.
English: It is not intended to provide practical advice on how to use Rivastigmine 3M Health Care Ltd.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Rivastigmine 3M Health Care Ltd.
English: Because Rivastigmine 3M Health Care Ltd is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Exelon.
Croatian: Budući da je Rivastigmine 3M Health Care Ltd generički lijek, ispitivanja na ljudima ograničena su na testiranja kojima se utvrdila bioekvivaletnost s referentnim lijekom, Exelon.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Rivastigmine 3M Health Care Ltd has been shown to have comparable quality and to be bioequivalent to Exelon.
Croatian: Povjerenstvo za lijekove za primjenu kod ljudi (CHMP) pri Agenciji zaključilo je da je Rivastigmine 3M Health Care Ltd dokazano usporediva lijeku Exelon u skladu sa zahtjevima EU.
English: What measures are being taken to ensure the safe and effective use of Rivastigmine 3M Health Care Ltd?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Rivastigmine 3M Health Care Ltd?
English: Rivastigmine 3M Health Care Ltd rivastigmine
Croatian: Rivastigmine 3M Health Care Ltd rivastigmin
English: What is Rivastigmine 3M Health Care Ltd and what is it used for?
Croatian: Što je Rivastigmine 3M Health Care Ltd i za što se koristi?
English: Rivastigmine 3M Health Care Ltd is a medicine that contains the active substance rivastigmine.
Croatian: Rivastigmine 3M Health Care Ltd je lijek koji sadrži djelatnu tvar rivastigmin.
English: A risk management plan has been developed to ensure that Rivastigmine 3M Health Care Ltd is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Rivastigmine 3M Health Care Ltd.
English: For practical information about using Rivastigmine 3M Health Care Ltd, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o korištenju lijeka Rivastigmine 3M Health Care Ltd pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
English: Other information about Rivastigmine 3M Health Care Ltd
Croatian: Ostale informacije o lijeku Rivastigmine 3M Health Care Ltd
English: What are the benefits and risks of Rivastigmine 3M Health Care Ltd?
Croatian: Koje su koristi i rizici povezani s lijekom Rivastigmine 3M Health Care Ltd?
English: Why is Rivastigmine 3M Health Care Ltd approved?
Croatian: Zašto je lijek Rivastigmine 3M Health Care Ltd odobren?
English: How does Rivastigmine 3M Health Care Ltd work?
Croatian: Kako djeluje Rivastigmine 3M Health Care Ltd?
English: See the summary of product characteristics (also part of the EPAR) for detailed information.
Croatian: Potpune informacije dostupne su u sažetku opisa svojstava lijeka (također dio EPAR-a).
English: How is Rivastigmine 3M Health Care Ltd used?
Croatian: Kako se Rivastigmine 3M Health Care Ltd koristi?
English: How has Rivastigmine 3M Health Care Ltd been studied?
Croatian: Kako se ispitivao lijek Rivastigmine 3M Health Care Ltd?
English: The main measure of effectiveness was based on the reduction in the number of episodes of laughing or crying.
Croatian: Glavna mjera djelotvornosti temeljena je na smanjenju broja epizoda smijeha ili plača.
English: The CHMP also noted that there is currently no treatment available for this distressing condition.
Croatian: Nadalje, CHMP je zaključio da trenutno ne postoji liječenje za ovo iscrpljujuće stanje.
English: The full EPAR for Nuedexta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) može se naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: • who are taking or have taken within the last 14 days medicines for depression called monoamine oxidase inhibitors (MAOI).
Croatian: • koji uzimaju ili su uzimali unutar 14 posljednjih dana lijekove protiv depresije naziva inhibitori monoaminoksidaze (MAOI).
English: Nuedexta must not be used in patients:
Croatian: Lijek Nuedexta ne smiju uzimati bolesnici:
English: Treatment should be started with one lower strength capsule (15mg/9mg) once a day (in the morning), which is increased after one week to twice a day (in the morning and evening, 12 hours apart).
Croatian: Preporuča se početak liječenja s jednom kapsulom manje doze (15 mg/9 mg) jednom na dan (ujutro), što se povećava nakon jednog tjedna uzimanja lijeka na dvaput na dan (ujutro i navečer, s razmakom od 12 sati).
English: Other information about Nuedexta
Croatian: Druge informacije o lijeku Nuedexta
English: • who are taking the medicine thioridazine used for mental illness;
Croatian: • koji već uzimaju lijek tioridazin koji se koristi za mentalne bolesti;
English: Serious side effects reported include muscle spasticity (excessive stiffness of muscles), respiratory depression (inhibition of breathing) and decreased oxygen saturation (lower-than-normal levels of oxygen) in the blood.
Croatian: Ozbiljne prijavljivane nuspojave uključuju spastičnost mišića (prekomjernu ukočenost mišića), depresiju disanja (prekomjerno sporo ili plitko disanje) i smanjenu zasićenost krvi kisikom (razine kisika niže od normalnih) u krvi.
English: The study also measured the change in the patients' symptoms, assessed in several ways including using a standard scale (called a CNS-LS score which ranges from 7 to 35).
Croatian: Ispitivanjem je također mjerena promjena u simptomima bolesnika, što je validirano na nekoliko načina, uključujući i primjenu standardne ljestvice (naziva ljestvica CNS-LS čiji se rezultati kreću od 7 do 35 bodova).
English: • with ‘prolonged QT interval' (a disruption of the electrical activity of the heart);
Croatian: • s produljenim "QT intervalom" (poremećajem električne aktivnosti srca);
English: After 12 weeks of treatment with Nuedexta, the CNS-LS score decreased by 8.2 points, compared with a decrease of 5.7 points for placebo.
Croatian: Nakon 12 tjedana liječenja lijekom Nuedexta, rezultati ljestvice CNS-LS smanjili su se za 8.2 boda, naspram smanjenja za 5.7 bodova za placebo.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Nuedexta's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za ljudsku uporabu (CHMP) Agencije zaključio je, da su dobrobiti lijeka Nuedexta veće od rizika lijeka, te je preporučio da se lijek odobri za uporabu u EU.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nuedexta on 24 June 2013.
Croatian: Europska komisija izdaje odobrenje za stavljanje u promet koje za lijek Nuedexta vrijedi na prostoru Europske unije od na 24. lipanj 2013.
English: PBA is a condition where damage to certain areas of the brain results in sudden and uncontrollable episodes of crying or laughing that do not relate to the patient's real emotional state.
Croatian: PBA je stanje u kojem oštećenje određenih područja mozga rezultira iznenadnim epizodama plača ili smijeha koje se ne mogu kontrolirati, a koje su u nerazmjeru s bolesnikovim emocionalnim stanjem.
English: A decrease in the total score indicates an improvement in PBA symptoms.
Croatian: Smanjenje ukupnog rezultata ukazuje na poboljšanje simptoma pseudobulbarnog afekta.
English: Since these neurotransmitters are involved in the control of emotions, dextromethorphan helps to normalise its activity in the brain, reducing the symptoms of PBA.
Croatian: S obzirom da ovi neurotransmitori sudjeluju u kontroli emocija, dekstrometorfan pomaže pri normalizaciji njihove aktivnosti u mozgu te na ovaj način smanjuje simptome pseudobulbarnog afekta.
English: A risk management plan has been developed to ensure that Nuedexta is used as safely as possible.
Croatian: Razvijen je plan upravljanja rizicima kako bi se osigurala što sigurnija uporaba lijeka Nuedexta.
English: Nuedexta is available as capsules (15 mg or 23 mg dextromethorphan and 9 mg quinidine) and can only be obtained with a prescription.
Croatian: Lijek Nuedexta dostupan je u kapsulama (15 mg ili 23 mg dekstromehorfana i 9 mg kinidina) i izdaje se samo na recept.
English: Regarding its safety, the CHMP decided that dextromethorphan and quinidine have been marketed as medicines for a number of years and their safety and interactions with other medicines are relatively well known.
Croatian: Vezano uz sigurnost, CHMP je zaključio, da su lijekovi dekstrometorfan i kinidin dostupni na tržištu kao lijekovi već godinama, te da su sigurni, a njihove interakcije s drugim lijekovima relativno su dobro poznate.
English: Dextromethorphan / quinidine
Croatian: Nuedexta dekstrometorfan / kinidin
English: The most common side effects with Nuedexta (which may affect up to 1 in 10 people) are diarrhoea, nausea (feeling sick), dizziness, headache, somnolence (sleepiness) and fatigue (tiredness).
Croatian: Najčešće prijavljivane nuspojave lijeka Nuedexta (koje se mogu pojaviti kod 1 od 10 bolesnika) uključuju proljev, mučninu (osjećaj slabosti), omaglicu, glavobolju, omamljenost (pospanost) i malaksalost (umor).
English: In addition, the company that makes Nuedexta must ensure that all healthcare professionals who are expected to use Nuedexta receive an information pack and a patient alert card with key safety information.
Croatian: Nadalje, društvo koje proizvodi lijek Nuedexta mora osigurati da svi zdravstveni djelatnici, za koje se očekuje da će koristiti lijek Nuedexta, zaprime informacijski paket i karticu s upozorenjima za bolesnika s ključnim sigurnosnim informacijama.
English: Although the exact way dextromethorphan works in PBA is unclear, it attaches to several different nerve cell receptors in the brain such as NMDA receptors and sigma-1 receptors for the neurotransmitter glutamate as well as receptors for the neurotransmitter serotonin.
Croatian: Iako točan način djelovanja dekstrometorfana u slučaju pseudobulbarnog afekta nije jasno utvrđen, dekstrometorfan veže se na nekoliko različitih receptora živčanih stanica u mozgu, poput receptora NMDA i receptora sigma-1 za neurotransmiter glutamat kao i na receptore za neurotransmiter serotonin.
English: What is Nuedexta and what is it used for?
Croatian: Što je lijek Nuedexta i za što se koristi?
English: • with a history suggestive of torsades de pointes ventricular tachycardia (abnormal heart rhythms);
Croatian: • s poviješću bolesti koja ukazuje na ventrikularnu tahikardiju torsades de pointes (abnormalni srčani ritmovi);
English: This is a summary of the European public assessment report (EPAR) for Nuedexta.
Croatian: Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Nuedexta.
English: Nuedexta was compared with placebo (a dummy treatment) for 12 weeks.
Croatian: Lijek Nuedexta ispitan je usporedno s placebom (lažnim liječenjem) u razdoblju od 12 tjedana.
English: • who are already being treated with the medicines quinidine, quinine or mefloquine or who have previously developed certain serious problems such as thrombocytopenia (low platelet counts) due to the use of these medicines;
Croatian: • koji se već uzimaju lijekove kinidin, kinin ili meflokin ili koji su u prošlosti imali određenih ozbiljnih tegoba, poput trombocitopenije (smanjen broj trombocita u krvi), prouzročenih uzimanjem jednog od navedenih lijekova;
English: Nuedexta is a medicine that contains two active substances, dextromethorphan and quinidine.
Croatian: Nuedexta je lijek, koji sadrži dvije djelatne tvari dekstrometorfan i kinidin.
English: For more information about treatment with Nuedexta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Nuedexta pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Although the exact cause of PBA is unclear, it is believed that it affects the way signals are transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
Croatian: Iako točan uzrok pseudobulbarnog afekta nije jasno utvrđen, vjeruje se da pseudobulbarni afekt utječe na način na koji „neurotransmiteri“, kemijske tvari koje omogućuju međusobnu komunikaciju živčanih stanica, prenose signala između moždanih stanica.
English: The company will also carry out a study on the use of Nuedexta and a study to monitor Nuedexta's safety including its effects on the heart and potential for interactions with other medicines.
Croatian: Društvo će također provesti ispitivanje o uporabi lijeka Nuedexta kao i ispitivanje o praćenju sigurnosti lijeka Nuedexta, uključujući i djelovanje lijeka na srce kao i mogućnost interakcija s drugim lijekovima.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Nuedexta, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju ovog plana, sigurnosne su informacije uključene u sažetak opisa svojstva lijeka i uputu o lijeku za lijek Nuedexta, uključujući i odgovarajuće mjere opreza kojih se moraju pridržavati zdravstveni djelatnici i bolesnici.
English: Why has Nuedexta been approved?
Croatian: Zašto je lijek Nuedexta odobren?
English: The role of quinidine is to prevent dextromethorphan from being broken down early in the body and thereby it prolongs the action of dextromethorphan in the body.
Croatian: Kinidin sprječava rano rastvaranje dekstrometorfana u tijelu, te ujedno produžuje djelovanje dekstrometorfana u tijelu.
English: What is the risk associated with Nuedexta?
Croatian: Koji su rizici povezani s lijekom Nuedexta?
English: Treatment with Nuedexta was effective in reducing patients' PBA episodes which were reduced by nearly 50% more than in patients treated with placebo.
Croatian: Liječenje lijekom Nuedexta bilo je djelotvorno u smanjivanju broja epizoda pseudobulbarnog afekta kod bolesnika, koje su smanjene za skoro 50% u odnosu na bolesnike liječene placebom.
English: What benefits of Nuedexta have been shown in studies?
Croatian: Koje koristi lijeka Nuedexta su dokazane u ispitivanjima?
English: In patients whose response is inadequate after four weeks, the higher strength capsule (23mg/9mg) may be used twice a day.
Croatian: Ako lijekom nije postignut odgovarajući klinički odgovor kod bolesnika nakon četiri tjedna, potrebno je prepisati kapsule više doze (23 mg/9 mg), koje se uzimaju dvaput na dan.
English: The main safety issues were considered manageable and adequately addressed by risk minimisation measures.
Croatian: Utvrđeno je da su glavni sigurnosni problemi savladivi te da se rješavaju na primjeren način mjerama za smanjivanje rizika.
English: • with or at high risk of complete AV block (a type of heart rhythm disorder);
Croatian: • s potpunim atrioventrikularnim (AV) blokom ili koji su izloženi riziku istog (tip poremećaja srčanog ritma);
English: Nuedexta has been studied in one main study involving 326 patients with PBA due to multiple sclerosis or amyotrophic lateral sclerosis.
Croatian: Lijek Nuedexta ispitan je u jednom glavnom ispitivanju, u kojem je sudjelovalo 326 bolesnika s pseudobulbarnim afektom u kojih su temeljne bolesti bile multipla skleroza ili amiotrofna lateralna skleroza.
English: What measures are being taken to ensure the safe use of Nuedexta?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Nuedexta?
English: The CHMP concluded that Nuedexta is effective in treating the symptoms of PBA based on the studies in patients with PBA caused by multiple sclerosis and amyotrophic lateral sclerosis.
Croatian: CHMP je zaključio da je lijek Nuedexta djelotvoran u liječenju simptoma pseudobulbarnog afekta na temelju ispitivanja provedenih u bolesnika s pseudobulbarnim afektom u kojih su temeljne bolesti bile multipla skleroza ili amiotrofna lateralna skleroza.
English: It is used to treat the symptoms of pseudobulbar affect (PBA) in adults.
Croatian: Lijek Nuedexta upotrebljava se za liječenje simptoma pseudobulbarnog afekta (PBA) u odraslih.
English: How does Nuedexta work?
Croatian: Kako lijek Nuedexta djeluje?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nuedexta.
Croatian: Objašnjava kako je Agencija ocijenila lijek da bi preporučila njegovo odobrenje u EU te uvjete za njegovu primjenu.
English: For the full list of all side effects reported with Nuedexta, see the package leaflet.
Croatian: Detaljan popis svih nuspojava prijavljenih za lijek Nuedexta dostupan je u uputi o lijeku.
English: How is Nuedexta used?
Croatian: Kako se lijek Nuedexta koristi?
English: For the full list of restrictions, see the package leaflet.
Croatian: Detaljan popis ograničenja dostupan je u uputi o lijeku.
English: Beecham PortuguesaProdutos Farmacêuticos e Químicos, Lda.
Croatian: Beecham Portuguesa - Produtos Farmacêuticos e Químicos, Lda.
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States
Croatian: Dodatak I Popis naziva, farmaceutskih oblika, jačina lijeka, puteva primjene, nositelja odobrenja u državama članicama raspadljiva tableta kroz usta N/A
English: GlaxoSmithKline, S.A. PTM- Severo Ochoa, 2 28760-Tres Cantos (Madrid) Spain
Croatian: GlaxoSmithKline, S.A. PTM- Severo Ochoa, 2 28760-Tres Cantos (Madrid) Španjolska
English: 1 g/vial
Croatian: 1 g/bočica
English: SmithKline Beecham Limited, 980 Great West Road Brentford Middlesex TW8 9GS United Kingdom
Croatian: SmithKline Beecham Limited, 980 Great West Road Brentford Middlesex TW8 9GS Velika Britanija
English: Clamoxyl 750 mg comprimidos
Croatian: Clamoxyl 750 mg comprimidos tableta
English: Arquiparque-Miraflores 1495-131 Algés Portugal
Croatian: Rua Dr. António Loureiro Borges, 3 Arquiparque-Miraflores 1495-131 Algés
English: Amoxil sachets 3g sucrose free
Croatian: Amoxil sachets 3g sucrose free kroz usta 3 g
English: Dispersible tablet
Croatian: Grčka raspadljiva tableta
English: Amoxil Vials 500mg, powder for solution for injection or infusion
Croatian: Amoxil Vials 500mg, powder for solution for injection or infusion prašak za otopinu za injekciju ili infuziju
English: Amoxil 3g Powder for Oral Suspension Sachets
Croatian: Amoxil 3g Powder for Oral Suspension Sachets prašak za oralnu suspenziju (vrećice)
English: Clamoxyl 1g comprimidos 1 g
Croatian: Clamoxyl 1g comprimidos tableta
English: Clamoxyl 500 mg cápsulas 500 mg Capsule, hard
Croatian: Clamoxyl 500 mg cápsulas kapsula, tvrda
English: Amoxicilline Biogaran 500 mg Capsule
Croatian: Amoxicilline Biogaran 500 mg kapsula
English: GlaxoSmithKline (Ireland) Ltd
Croatian: GlaxoSmithKline (Ireland) Ltd Stonemasons Way Rathfarnham
English: Clamoxyl 1 g polvo para suspensión oral en sobre
Croatian: Clamoxyl 1 g polvo para suspensión oral en sobre 1 g
English: 266 Kifisias Avenue 152 32 Halandri Greece
Croatian: GlaxoSmithKline a.e.b.e. 266 Kifisias Avenue 152 32 Halandri Grčka
English: Intramuscular
Croatian: Cipar
English: Amoxil Vials for Injection 1 g
Croatian: Amoxil Vials for Injection prašak za otopinu za injekciju
English: Powder and solvent for solution for injection
Croatian: Luksemburg prašak i otapalo za otopinu za injekciju